Significance
Sialidase activity in the vaginal microbiome is increased in bacterial vaginosis and strongly associated with other adverse health outcomes. Sialidase enzymes release sialic acid from host-derived glycans in the vaginal environment, altering their structures and functions. However, biochemical studies of vaginal bacterial sialidases have been limited to one genus, Gardnerella. In this work, we identify and characterize multiple sialidase enzymes in vaginal bacteria of the genus Prevotella, including an enzyme active toward human mucin. We find that genes and transcripts encoding Prevotella sialidases are more prevalent and abundant in vaginal microbial communities than those from Gardnerella. Our work highlights Prevotella bacteria as an underappreciated source of sialidase transcripts in metatranscriptomes with important implications for our understanding of sialidase producers in the vaginal ecosystem.
Keywords: sialidase, mucin, bacterial vaginosis, vaginal microbiome, Prevotella
Abstract
Elevated bacterial sialidase activity in the female genital tract is strongly associated with poor health outcomes including preterm birth and bacterial vaginosis (BV). These negative effects may arise from sialidase-mediated degradation of the protective mucus layer in the cervicovaginal environment. Prior biochemical studies of vaginal bacterial sialidases have focused solely on the BV-associated organism Gardnerella vaginalis. Despite their implications for sexual and reproductive health, sialidases from other vaginal bacteria have not been characterized. Here, we show that vaginal Prevotella species produce sialidases that possess variable activity toward mucin substrates. The sequences of sialidase genes and their presence are largely conserved across clades of Prevotella from different geographies, hinting at their importance globally. Finally, we find that Prevotella sialidase genes and transcripts, including those encoding mucin-degrading sialidases from Prevotella timonensis, are highly prevalent and abundant in human vaginal genomes and transcriptomes. Together, our results identify Prevotella as a critical source of sialidases in the vaginal microbiome, improving our understanding of this detrimental bacterial activity.
The microbial community that inhabits the human vagina (the vaginal microbiome) is important for sexual and reproductive health. The composition of the vaginal microbiome can differ substantially between individuals (1). While beneficial health outcomes have been associated with Lactobacillus-dominated vaginal microbiomes, more diverse communities containing anaerobic bacteria have been associated with increased risk for preterm birth, bacterial vaginosis (BV) (2), and HIV acquisition (3). Despite these strong connections to health, the specific mechanisms by which vaginal bacteria influence the host are poorly understood. An understanding of the vaginal bacterial functions most strongly linked to adverse health outcomes is needed to enhance our understanding of this microbial community and guide the design of vaginal microbiome-targeted therapeutics.
Elevated sialidase activity in vaginal fluid is associated with increased risk of preterm birth (4, 5) and is a common feature of BV (6–8). Sialidases are glycoside hydrolase (GH) enzymes that hydrolyze terminal sialic acids (such as N-acetyl-neuraminic acid, Neu5Ac) from glycans present on proteins and lipids (Fig. 1A). Multiple, varied sources of sialic acid are found in the female genital tract. Sialic acids are incorporated into the terminal end of mucin glycans, which are prominent components of the mucus layer that covers cervical and vaginal epithelial cells. Cervical mucus secretions contain gel-forming mucins (MUC5B, MUC5AC, and MUC6) as well as transmembrane mucins (MUC16 and MUC1), with MUC5B being the most abundant (9). Immunoglobulins in the cervical mucus (e.g., IgG) are also sialylated, and sialic acids are important for antibody regulation and function (10, 11). Changes in mucus properties are linked to preterm birth risk (12), suggesting that the activity of sialidases on mucins could have implications for mucus function and host health.
Fig. 1.
Vaginal Prevotella species encode diverse sialidases. (A) Vaginal bacteria sialidase enzymes are hypothesized to remove sialic acids (such as Neu5Ac) from the mucin glycans that comprise the protective mucus layer covering vaginal epithelial cells. (B) Prevotella timonensis CRIS 5C-B1, Prevotella bivia DNF00188, Prevotella denticola DNF00960, and Prevotella amnii CRIS21A-A encode proteins with predicted sialidase domains. Previously characterized Gardnerella sialidases’ protein domains are also displayed for comparison. Individual colors represent different domains and features: signal peptide (red), sialidase domain IPR011040 (green), and carbohydrate binding domain 93 (blue). The amino acid length is displayed for each bar. (C) Prevotella isolates display sialidase activity that correlates with the presence of candidate sialidase genes, indicated by +/–. Bacterial isolates were cultured in PYGT media containing 1 % glucose and 10 % horse serum. Sialidase activity was measured in whole culture samples. Positive control represents the full hydrolysis of 4-methylumbelliferyl N-acetyl-α-D-neuraminic acid (4-MU-Neu5Ac) by Arthrobacter ureafaciens sialidase (AUS). Gardnerella vaginalis ATCC14018 is indicated as a (–) because it encodes NanH1 but not NanH2 or NanH3. G. vaginalis JCP8066 encodes NanH1 and NanH3. Data represent the average ± SD of >5 biological replicates. Significance was assessed using one-way ANOVA followed by the multiple comparisons test, ****P < 0.0001, *P < 0.05. Significance values represent comparison to the media blank.
Sialidase activity in the female genital tract has long been attributed to the anaerobic vaginal bacterium G. vaginalis, which can encode up to three different sialidases (NanH1, NanH2, and NanH3) (13). The nanH1 gene (previously sialidase A), which is highly prevalent in Gardnerella-positive vaginal samples (13–15), was the first sialidase gene identified (16) in this organism and was assumed to be responsible for sialidase activity without biochemical characterization of the corresponding protein. However, recent biochemical characterization of this enzyme showed it has little activity toward the sialidase substrate 4-methylumbelliferyl N-acetyl-α-D-neuraminic acid (4-MU-Neu5Ac) (13). Lacking a signal peptide, NanH1 is also predicted to be intracellular, making it unlikely to interact with mucin. In contrast, the extracellular enzymes NanH2 and NanH3 display greatly increased activity toward 4-MU-Neu5Ac and can efficiently remove sialic acids from bovine submaxillary mucin (BSM) (13, 17, 18).
Accumulating evidence suggests sialidase activity may be more widespread among vaginal bacteria. For example, several studies have found that Prevotella bivia (7), P. timonensis (also called Hoylesella timonensis), and Bacteroides fragilis strains isolated from vaginal samples possess sialidase activity (6, 19, 20). A recent analysis of transcriptomes found that Prevotella species express a large fraction of predicted sialidase genes (annotated by the Carbohydrate Active enZymes database, CAZy) in diverse vaginal samples (21). Prevotella strains also have been isolated from the upper reproductive tract (22) and their abundance in the vagina is correlated with preterm birth (23, 24). Persistent sialidase activity in women with recurrent BV has also previously been associated with P. bivia (6). P. timonensis isolates can alter the endometrial epithelial barrier and induce mucin expression (MUC3 and MUC4) in a 3D epithelial cell model (20). P. timonensis presence in early pregnancy is also a predictor for higher risk of preterm birth (2). Despite the intriguing links between sialidase activity, preterm birth, and Prevotella, putative sialidases from these bacteria have not been biochemically characterized and their activities remain poorly understood.
Here, we investigate sialidases from vaginal Prevotella species as a first step toward understanding their contributions to sialidase activity in the female genital tract. We initially biochemically characterize sialidases from three Prevotella species in vitro, observing unexpected differences in activity toward mucin substrates, including the human mucin MUC5B. We use comparative genomics to demonstrate that genes encoding sialidases are widely distributed across vaginal Prevotella isolates from the United States and South Africa and their sequences and presence are largely conserved within phylogenetic groups. Finally, through analysis of human vaginal metagenomes (MG) and metatranscriptomes (MT), we find that P. timonensis sialidase-encoding genes and transcripts are more prevalent than sialidase-encoding genes from other vaginal bacteria, including G. vaginalis. These findings reveal Prevotella bacteria as important, underappreciated contributors to sialidase activity in the human vaginal microbiome and highlight a need to understand the biological roles of these enzymes in the vaginal environment.
Results
Vaginal Prevotella Species Encode Diverse Sialidases.
To identify candidate sialidase genes in vaginal Prevotella, we initially analyzed seven publicly available genomes of from vaginal isolates of P. bivia, P. amnii, P. denticola, P. disiens, and P. timonensis from BEI Resources (Biodefense and Emerging Infections). Sequences of biochemically characterized sialidases from Gardnerella (NanH2 and NanH3) were used as query. We found five genes encoding candidate sialidases in four Prevotella species, P. bivia DNF00188 (PbnanH), P. amnii CRIS21A-A (PananH), P. denticola DNF00960 (PdnanH), and P. timonensis CRIS 5C-B1 (PtnanH1 and PtnanH2) (SI Appendix, Fig. S1). All five proteins contain the catalytic active site residues characteristic of the GH33 family of sialidases (SI Appendix, Fig. S2 and Table S5). All sequences also contain a predicted signal peptide, indicating they are likely extracellular, and a sialidase catalytic domain (IPR011040) (Fig. 1B) with the predicted β-propeller fold characteristic of these enzymes (SI Appendix, Figs. S3–S5). PbNanH and PaNanH also contain a predicted carbohydrate-binding domain 93, which is typically found in sialidases from commensal gut Bacteroides (25). We found that P. timonensis encodes two sialidases of different lengths (PtNanH1 413 amino acids; PtNanH2 1,030 amino acids) and AlphaFold (26) structure prediction indicates PtNanH2 may contain four additional domains of unknown function which are not homologous to structurally characterized protein domains (SI Appendix, Fig. S5B).
We next cultured available vaginal Prevotella isolates in PYGT medium with 1 % glucose and 10 % horse serum and tested for sialidase activity in culture using the fluorescent substrate 4-MU-Neu5Ac. Notably, of all strains tested, P. timonensis CRIS 5C-B1 consistently had the highest sialidase activity (Fig. 1C). Sialidase activity in G. vaginalis JCP8066, which encodes NanH3, was detectable but variable across different experiments. Other Prevotella strains, such as P. bivia (24), encoding sialidases had low but detectable activity. No activity was observed for a P. disiens DNF00882 isolate lacking a sialidase homolog. Together, this work further confirmed the presence of sialidase activity in vaginal Prevotella strains and identified candidate sialidase enzymes for biochemical studies.
Prevotella Sialidases Are Active and Susceptible to Inhibition.
To determine whether the predicted Prevotella sialidase genes encoded active sialidase enzymes, we expressed the putative sialidases from P. timonensis CRIS 5C-B1, P. bivia DNF00188, and P. denticola DNF00960 in Escherichia coli and purified them for in vitro biochemical characterization (SI Appendix, Fig. S6). We found all purified Prevotella sialidases were active toward 4-MU-Neu5Ac (Fig. 2A). The kinetics of vaginal bacterial sialidases have not yet been examined; we therefore determined the Michaelis–Menten kinetic parameters of the Prevotella sialidases and GvNanH3. We found their turnover rates kcat (110.46 to 149.33 s−1) and catalytic efficiencies kcat/Km (0.51 to 1.83 × 106 s−1 M−1) (SI Appendix, Table S6) comparable to those of other previously characterized bacterial sialidases (SI Appendix, Table S7).
Fig. 2.
Prevotella sialidases are active at varying pH levels and are inhibited by small molecules. (A) Purified sialidase enzymes hydrolyze 4-MU-Neu5Ac, indicating they possess sialidase activity. For each time point, 2.5 nM enzyme was incubated with 200 µM 4-MU-Neu5Ac in sodium acetate buffer, pH 5.5 at 37 °C. Data represent the average + SEM of three independent experiments. (B) Sialidase activity at varying pH. 200 µM 4-MU-Neu5Ac was prepared in 0.1 M citric acid/0.2 M phosphate buffer at pH values ranging from 3 to 8. Data represent the average ± SEM of three independent experiments. Inhibitory activity of (C) Neu5Ac2en and (D) Zanamivir toward Prevotella and Gardnerella sialidases (IC50 values can be found in SI Appendix, Table S8). Purified sialidases were preincubated with inhibitor for 15 min before adding 4-MU-Neu5Ac to determine activity. Data represent the average ± SEM of three independent experiments.
Health-associated Lactobacillus-dominated vaginal communities have a pH < 4.51, while Prevotella species are typically found in more diverse vaginal communities which have a pH > 4.5. We therefore examined the pH dependence of the Prevotella sialidases and GvNanH3. Measuring the activity of the Prevotella sialidases toward 4-MU-Neu5Ac over a pH range of 3.0 to 8.0 revealed that all sialidases had maximal activity above pH 4.5 (Fig. 2B). Interestingly, among the tested enzymes PtNanH1, PtNanH2, and GvNanH3 displayed activity below pH 4 while PdNanH was only active above pH 4.8.
To further confirm the functional assignment of these enzymes, we examined their susceptibility to various commercially available sialidase inhibitors. All enzymes were inhibited by the well-characterized, broad-spectrum sialidase inhibitor, Neu5ac2en (Fig. 2C and SI Appendix, Table S8) (27). Unexpectedly, the viral sialidase inhibitor Zanamivir (Relenza) was effective toward P. timonensis CRIS 5C-B1 sialidases PtNanH1 and PtNanH2 but no other enzymes tested (Fig. 2D). Inhibition of sialidase activity by Neu5Ac2en and Zanamivir was also observed in P. timonensis cultures (SI Appendix, Fig. S8). Overall, these results further support the characterization of these enzymes as sialidases, with the variable activity of Zanamivir suggesting potential differences in structure and function between the P. timonensis sialidases and those from other Prevotella species.
Prevotella Sialidases Have Variable Activity Toward Mucin Glycoproteins.
Sialic acids are incorporated into a variety of potential substrates, including mucin glycans, via α2-3′ and α2-6′ linkages. We sought to determine whether Prevotella sialidases had differences in linkage and substrate preferences by testing their activity toward a panel of six Neu5Ac-containing substrates (Fig. 3A). We incubated purified sialidases with α2-3′-sialyllactose (3′SL), α2-6′-sialyllactose (6′SL), BSM, human salivary MUC5B, immunoglobulins A (IgA), and immunoglobulins G (IgG), and quantified Neu5Ac released by each enzyme in an endpoint liquid chromatography–mass spectrometry (LC–MS) assay. Salivary MUC5B and BSM were used because they share certain sialylation patterns and linkages [α(2,3) Neu5Ac bound to galactose and α(2, 6) Neu5Ac bound to GalNAc] with cervical MUC5B (SI Appendix, Fig. S9). Although the precise sialylation patterns of cervical immunoglobulins are unknown, we used commercially available IgG and IgA, which have been previously used as substrates for vaginal bacterial sialidase activity (17, 28). We found that all sialidases released sialic acid from 3′SL and 6′SL substrates, indicating these sialidases do not have a strong preference for linkage type (Fig. 3A). All sialidases tested released sialic acid from IgA and IgG, the predominant immunoglobulins in cervical mucus (29, 30) (Fig. 3A). Unexpectedly, the Prevotella sialidases differed in their activity toward mucin substrates. While PtNanH2 and GvNanH3 efficiently removed sialic acid from both BSM and human MUC5B, PtNanH1, PbNanH, and PdNanH had reduced activity (30 to 40%) toward BSM and little to no activity toward MUC5B (Fig. 3 B and C). The variable activity of vaginal bacterial sialidases toward the human mucin MUC5B is unexpected given the potential links between mucin degradation and negative health outcomes.
Fig. 3.
Prevotella sialidases have varied substrate specificities. (A) Quantification of sialidase activity toward different substrates: 4-MU-Neu5Ac, 3′SL and 6′SL, human serum IgG, and human serum IgA. Purified sialidase enzyme (20 to 100 nM) was incubated with each substrate in 20 mM sodium acetate buffer pH 5.5 for 2 h at 37 °C. AUS was used a positive control to release the total sialic acid from each substrate (31). Sialidase activity toward (B) BSM and (C) purified human salivary MUC5B. (D) Structures of Neu5Ac and N-glycolylneuraminic acid (Neu5Gc). Data represent the average ± SEM of three independent experiments. N.D. represents values were not detected below the limit of detection. (E) Sialidase activity toward Neu5Gc from BSM. Data represent the average ± SEM of three independent experiments. Significance was assessed using one-way ANOVA followed by the multiple comparisons test, ****P < 0.0001, *P < 0.05. Significance values represent comparison to the no enzyme control.
We next sought to explore whether Prevotella sialidases could release other forms of sialic acid from BSM, which contains diverse sialic acid structures including Neu5Ac and Neu5Gc, Neu5,7Ac2, and Neu5,9Ac2. PbNanH resembles Sialidase26 (66% amino acid ID), recently characterized from the human gut MG (32), which has preferential activity toward Neu5Gc (Fig. 3D). While the presence of Neu5Gc in cervicovaginal mucins is unclear, this finding prompted us to assess whether vaginal bacterial sialidases could release Neu5Gc from BSM. Consistent with our previous assay results, PbNanH and PdNanH did not release Neu5Gc from BSM (Fig. 3E). Among the sialidases observed previously to release Neu5Ac from BSM, only PtNanH1, PtNanH2, and GvNanH3 also released Neu5Gc from this substrate, further indicating these enzymes are more promiscuous than the other sialidases (Fig. 3E). Together, the results of this substrate survey demonstrate Prevotella sialidases can release sialic acid from substrates resembling those found in the cervicovaginal environment. Notably, the P. timonensis CRIS 5C-B1 PtNanH2 possess similar reactivity to the previously reported active Gardnerella sialidase GvNanH313.
Sialidases Are Conserved in Prevotella Isolates From Different Geographies.
Having characterized the activities of the Prevotella sialidases, we next sought to determine the prevalence of sialidase genes across diverse strains of Prevotella and compare their distribution to that of other characterized and predicted vaginal bacterial sialidase genes. Employing an HMM-based approach using the sialidases characterized in this work and other GH33 sialidases from the CAZy database, we searched whole genomes from over 1,000 bacterial strains isolated from vaginal samples from cohorts based in the United States and South Africa (SI Appendix, Figs. S10 and S11). We observed that sialidase genes in P. timonensis and P. bivia are highly conserved within isolates of these species and that the encoded proteins share high amino acid ID. All 53 P. bivia isolates encode a highly similar PbNanH sialidase (>98% amino acid ID) regardless of the geography of origin. Similarly, all 21 P. timonensis isolates encode PtNanH2 (>93% amino acid ID) and 19/21 encode PtNanH1 (>94% amino acid ID) (Fig. 4A). Additionally, close relatives of P. timonensis also encode distantly related sialidase genes. A vaginal P. buccalis isolate encodes a sialidase with 61% amino acid ID to PtNanH1 but lacking a signal peptide. Prevotella colorans FRESH097 and P. sp16 C0026C3 encode a putative sialidase distinct from the ones characterized here with only 9% and 23% amino acid ID to PtNanH1, respectively, and both contain signal peptides (SI Appendix, Fig. S12). Interestingly, we did not detect any genes encoding sialidases in clades of P. disiens, Prevotella intermedia, Prevotella ihumii, or Prevotella corporis, and we did not find additional examples of vaginal P. denticola in these isolate collections. Inspecting the gene neighborhoods of these Prevotella sialidase genes revealed they are usually found near other genes encoding GH enzymes and are not usually colocalized with sialic acid metabolism genes, except for P. timonensis nanH1 which is near nanE (UDP-N-acetylglucosamine 2-epimerase) (Fig. 4B). Notably, sialidase activity experiments with additional strains of P. timonensis, P. bivia, and P. amnii showed consistent levels of sialidase activity across individual species, suggesting the presence of sialidase genes may be predictive of function (SI Appendix, Fig. S14).
Fig. 4.
Sialidases are widely distributed across Prevotella and Gardnerella isolates obtained from the United States and South African vaginal samples. Phylogenetic trees of vaginal isolates from the Vaginal Microbiome Research Consortium (N. American) and FRESH (S. African) studies. (A) Sialidase genes present in individual Prevotella isolate genomes (gene presence is shown as a filled circle). (B) Genome neighborhoods of Prevotella and Gardnerella sialidases. (C) Sialidase genes present in individual Gardnerella isolate genomes. The phylogeny is based on 49 concatenated ribosomal proteins and serves as a proxy for the core genome. The scale bar indicates nucleotides substitutions per site. Each genome was searched using the sialidase protein alignment with HMMER (version 3.1b2). See SI Appendix, Figs. S13 and S15 for the unrooted Prevotella and Gardnerella phylogenetic trees. * = 56% amino acid ID to PtNanH1, ** = 61% AA ID to PtNanH1, *** = 78% amino acid ID to PdNanH, **** = 70% amino acid ID to PbNanH. The orange filled circle indicates a sialidase that is unique from the Prevotella sialidases characterized here.
Gardnerella isolates varied in their sialidase content based on clade, as reported previously (33). Gardnerella swidsinskii and Gardnerella leopoldi did not encode any sialidases, while the other Gardnerella clades encode GnanH1 (61/73). Notably, the active sialidases GnanH2 (5/73) and GnanH3 (20/73) are much less prevalent than GnanH1 and are unevenly distributed across G. vaginalis and Gardnerella piotii strains (Fig. 4C). Interestingly, this analysis revealed variants of GnanH1 exist among different Gardnerella clades. For example, a variant of NanH1 found in Gardnerella isolates from the United States shares 82 % amino acid ID with NanH1 found in Gardnerella strains from South Africa. The G. vaginalis JCP8066 NanH3 enzyme used in this study is homologous to G. piotii NanH3 (92% amino acid ID). We also identified an additional candidate sialidase, called NanH4, in 12 G. vaginalis isolates; however, NanH4 may be inactive since we verified (via BLAST) it is found in G. vaginalis ATCC 49145, which does not demonstrate sialidase activity in culture, and is predicted to be intracellular (13).
We also found putative GH33 sialidases encoded in diverse vaginal isolates from the genera Bacteroidales, Bacteroides, Bifidobacterium, Corynebacterium (Actinomycetia), and Streptococcus (SI Appendix, Figs. S10 and S11). Streptococcus agalactiae encodes a sialidase that is >98% ID at the amino acid level to Group B Streptococcus NonA (34), an inactive homolog of the Streptococcus pneumoniae NanA sialidase. There was no sialidase present in its sister clade Streptococcus anginosus. Overall, this genome survey increases knowledge of vaginal bacterial sialidases by broadening the search to a wide variety of species and geographies. The substantial variability we observe in sialidase gene presence across certain vaginal bacterial species highlights a need to directly identify these enzymes in vaginal microbiomes rather than infer their presence from phylogenetic information.
P. timonensis Sialidase Genes and Transcripts Are Prominent in Vaginal Microbiomes.
We next identified the genes encoding biochemically characterized Prevotella and Gardnerella sialidases, as well as the additional putative sialidases from our genome survey, in human vaginal microbiomes. To quantify the differential abundance and prevalence of sialidase-encoding genes and transcripts, we performed translated nucleotide sequence searches in paired MG and MT from vaginal samples sequenced by France et al. (21) (Fig. 5A). These samples were collected from 39 reproductive-aged, nonpregnant women at up to 5 timepoints over the span of 10 wk. We analyzed all the samples individually and paired the MG and MT samples (n = 176) with the associated subject metadata to examine association of sialidase gene expression with community state type (CST), including L. crispatus–dominated (CSTI), L. gasseri–dominated (CSTII), L. iners–dominated (CSTIII), diverse anaerobic (CSTIV), and L. jensenii–dominated (CSTV) communities. We expected to find higher levels of sialidase gene expression in CSTIV communities compared to other CSTs since sialidase activity is detected in subjects with BV and is typically absent from Lactobacillus-dominated samples (6, 35). Unexpectedly, sialidase genes and transcripts were detected in a high percentage of all CSTs (69 to 100% of MGs and 56 to 90% of MTs) with the lowest prevalence found in CSTI samples. However, we found that CSTIV MGs encode a greater abundance of sialidase genes compared to all other CSTs (Fig. 5A). We also found that CSTIV MTs have significantly higher sialidase gene expression than MTs from CSTI and CSTIII samples (Fig. 5B).
Fig. 5.
Prevotella sialidase genes and transcripts are prevalent across vaginal community state types. (A) Total sialidase abundance and prevalence in paired MG and (B) MT samples (n = 176). Abundance was determined by Diamond blastX and displayed as reads per kilobase million (RPKM). The cutoff for sialidase prevalence is sialidase reads > 0. Significance was assessed by a one-way ANOVA followed by a Brown–Forsythe and Welch test, **P < 0.0001, **P < 0.01. (C and D) The abundance and prevalence of specific sialidase genes in all available samples (MG; n = 193, MT; n = 188). The figure displays sialidase genes with >15 % prevalence in MG samples. Abundance values were calculated by adding RPKM to a pseudocount (1E8). The diamond indicates the average sialidase expression across all samples ± SD. See complete list of representative sialidase genes in SI Appendix, Fig. S17. (E) Contribution of sialidase abundance within individual vaginal samples across MG and MT. Paired MG and MT were used to investigate the relative contribution of several vaginal sialidases. Stacked bar graphs are aligned to pair the corresponding MG and MT sample.
The prevalence of individual sialidase genes varied across all vaginal MGs: Gardnerella sialidase genes were detected in 23%–58% of samples, P. bivia (PbnanH 47% of samples), P. amnii (PananH 29% of samples), and P. timonensis sialidase genes (PtnanH1 51% and PtnanH2 62% of samples) were identified at similar frequencies, while the sialidase gene from P. denticola was not detected (0%), likely because this organism is rarely found in the vaginal microbiome (Fig. 5C). In vaginal MTs, P. timonensis sialidase transcripts were the most prevalent (PtnanH1 59% and PtnanH2 65% of samples) and abundant, followed by Gardnerella (GnanH1 38 to 48%, GnanH2 11%, GnanH3 19% of samples), P. amnii (PananH 25% of samples), and P. bivia (PbnanH 36% of samples), while P. denticola was not detected (PdnanH 0%) (Fig. 5D). Interestingly, Gardnerella nanH1 transcripts were more prevalent than those encoding the active Gardnerella sialidases (G. piotii nanH2 and nanH3). Sialidase genes from additional taxa identified in Fig. 4 have low prevalence in MGs (<15% of samples) and had minimal to no presence in the MTs.
The variable prevalence of different sialidase genes and transcripts across samples raised the question of their contributions to overall sialidase expression within individual samples. To determine which sialidase genes are expressed in individual vaginal microbiomes, we computed the percent contribution of all sialidases within paired MG and MT samples (Fig. 5E). We found that, although Gardnerella sialidase genes are present in MGs, sialidase genes from P. timonensis and other Prevotella contribute a higher percentage of reads in MTs across samples from all CSTs (Fig. 5E and SI Appendix, Fig. S16A). P. timonensis sialidase transcripts were also more prevalent than all Gardnerella sialidases across all CSTs (SI Appendix, Figs. S16–S22). We also repeated the analysis, excluding the predicted inactive Gardnerella sialidase genes GnanH1 and GnanH4 (SI Appendix, Fig. S23). This further demonstrated that Prevotella sialidases are the predominant genes and transcripts present across samples. Together these findings show that while both Prevotella and Gardnerella sialidase genes and transcripts are detected in vaginal samples, those from Prevotella are most prevalent and abundant across all CSTs. Importantly, this pattern is not simply a reflection of vaginal microbiome community composition, as previous analyses of these datasets revealed a higher abundance of Gardnerella (21). Altogether, our analyses indicate that Prevotella bacteria, particularly P. timonensis, are likely a predominant source of sialidase activity within the vaginal microbiome.
Discussion
Sialidase activity in the vaginal microbiome has been strongly linked to negative health outcomes, including BV and preterm birth. Thought to significantly alter the vaginal ecosystem, this metabolic activity may facilitate mucus degradation, release carbon sources for vaginal bacteria, and promote bacterial binding to mucins and host cell glycans by revealing cryptic binding sites (36, 37). Prior to our work, knowledge of sialidase enzymes in vaginal bacteria was largely limited to Gardnerella. Gardnerella encode three sialidases, NanH1 (which is poorly active) as well as NanH2 and NanH3, which display sialidase activity and are predicted to localize extracellularly. Other vaginal bacteria were reported to possess sialidase activity in culture, including P. bivia and P. timonensis (6, 20), with a recent report implicating P. timonensis sialidases in vaginal cell surface glycan degradation (37). Here, we combine bioinformatic analyses and biochemical experiments to identify Prevotella sialidase enzymes and assess their distribution across vaginal isolates and vaginal microbiomes.
Though enzyme-encoding genes can often be annotated in bacterial genomes, important aspects of their activity cannot be readily predicted from sequence alone, highlighting the importance of biochemical characterization. Indeed, our in vitro studies of vaginal sialidases revealed differences in pH activity range, activity toward mucin substrates, and susceptibility to inhibition. Our pH analysis reveals P. timonensis PtNanH1 and PtNanH2 and GvNanH3 are active at pH values <4.5 and >4.5, while the other Prevotella sialidases tested only displayed activity at pH >4.5. This finding suggests that P. timonensis sialidases may be active in the more acidic conditions generated by Lactobacillus-dominated communities. We found that only PtNanH2 and GvNanH3 accept mucin substrates (MUC5B and BSM) perhaps indicating a higher potential to alter the structure and function of these important host glycans. One caveat of our work is the use of salivary MUC5B (38) rather than cervical MUC5B, which is not readily available. Though salivary and cervical MUC5B are thought to share certain glycosylation patterns, including sialylation, additional studies from more subjects are needed to elucidate the structures of cervical mucins glycans (9).
Our findings add to growing evidence that vaginal bacterial sialidases alter the structures of host glycans, likely impacting their functions. A recent study found that membrane-bound glycans of human vaginal epithelial cells from subjects with BV have diminished sialylation and recapitulated this phenotype in cells with recombinant Gardnerella sialidases (GvNanH2 and GvNanH3) (39). This finding, along with a recent report that P. timonensis removes sialic acids from vaginal epithelial cell surfaces (37), further implicates vaginal bacterial sialidases in detrimental host phenotypes (37).
Viral and pathogenic bacterial sialidases have been targets for small molecule inhibitor development. While the broad-spectrum inhibitor Neu5Ac2en inhibited all vaginal bacterial sialidases, the viral sialidase inhibitor Zanamivir specifically inhibited both P. timonensis sialidases. Though we did not observe inhibition of GvNanH3 by Zanamivir in our experimental setup, it is possible that this enzyme can be partially inhibited as was previously reported (40). Segui Perez et al., demonstrate that removal of sialic acids from vaginal epithelial cell surface glycans by P. timonensis can be prevented by treatment with Neu5Ac2en and Zanamivir (37). Sialidase inhibitors are therefore useful tools to understand the effects of sialidase activity in the vaginal environment and could be further explored therapeutically.
Using comparative genomics, we found the sequences of Prevotella sialidase genes, and their presence, are more conserved across related strains compared to Gardnerella sialidases. Previous studies identified sialidase activity in most P. bivia isolates (33), but few studies have examined P. timonensis. Examining a diverse isolate genome collection also allowed us to find additional putative sialidases from closely related Prevotella species. We predict the newly identified Gardnerella sialidase GNanH4 is likely inactive, similar to GNanH1, since it also lacks a signal peptide and no strains encoding this gene are known to have sialidase activity. GNanH4 and GNanH1 have predicted Ig/Lectin-like domains that can also be found in Actinomyces sialidases, which have not been biochemically characterized. It is possible that GNanH1 and GNanH4 act intracellularly on as-yet-uncharacterized substrates given their lack of a signal peptide, or are inactive, similar to the Group B Streptococcus sialidase NonA (34). Future work should examine GNanH1 sialidase activity toward additional substrates such as human vaginal epithelial cell surface glycans (39), glycan arrays (41), or in more complex or natural settings (20, 42).
Our analyses of vaginal MGs and MTs reveal that most sialidase gene expression comes from Prevotella and Gardnerella while putative sialidase genes from other vaginal bacteria are rarely expressed. Among the Gardnerella sialidase genes, GnanH1 was the most prevalent in MTs. This is perhaps surprising considering experimental evidence shows GvNanH1 has extremely low activity toward sialylated substrates (13). GnanH1 may be more prevalent in MTs because it is more frequently found in Gardnerella genomes compared to GnanH2 and GnanH3 (15); however, it may also participate in an uncharacterized metabolic process. Notably, the genes encoding Gardnerella’s active sialidases, GnanH2 and GnanH3, were less prevalent than the P. timonensis sialidase genes PtnanH1 and PtnanH2 in this dataset, suggesting a reduced impact on host glycan metabolism. Together, these data suggest that, in addition to Gardnerella, P. timonensis makes a substantial contribution to vaginal sialidase activity.
Sialidases activity is considered a hallmark of BV8 and diverse CSTIV communities. Our data suggest sialidase genes and transcripts have the highest prevalence and abundance in CSTIV samples, however, we were surprised to detect sialidase gene expression in samples from other CSTs, including L. crispatus–dominated CSTI (SI Appendix, Fig. S15). The presence of sialidase genes and transcripts in other CSTs may suggest sialidases might be important in mediating transitions between CSTs. Although rare, several studies have detected sialidase activity in non-BV samples (6, 43, 44). We also noticed samples can vary in their sialidase expression profile, with some expressing three to four sialidases, while others express a single sialidase. This hints at the relevance of multiple, diverse sialidases in the vaginal environment, potentially creating a division of labor or even the potential for public good exploiters as seen in other ecosystems (45). We find that Prevotella sialidase transcripts are particularly prominent in MTs from all CSTs. Other studies have noted while the relative abundance of Prevotella species in vaginal MGs may be low (1), their genes can be highly expressed in MT data (21). In particular, the presence of P. timonensis sialidase transcripts in MTs from certain Lactobacillus-dominated communities suggests the possibility that these enzymes could contribute to community destabilization and transition to other CSTs.
Together, these bioinformatic analyses provide a more complete understanding of the origins of sialidase activity in the vaginal microbiome and highlight the importance of integrating bioinformatic analysis with detailed biochemical studies. Additional analyses of vaginal bacterial sialidase genes and transcripts in other clinical cohorts are needed, including pregnancy cohorts that could reveal links between specific sialidases and birth outcomes. A limitation of this work is that we did not biochemically characterize all the putative sialidases that were expressed in MTs to confirm their activity.
In summary, we demonstrate that Prevotella possess sialidase enzymes that likely play an important, currently underappreciated role in the vaginal microbiome, with P. timonensis standing out as a prominent source of sialidase enzymes and a major contributor of sialidase genes and transcripts in vaginal communities. A contemporary study also demonstrates that P. timonensis can efficiently adhere to the vaginal epithelium and that its sialidases and fucosidases are highly effective at removing glycans from the vaginal epithelial surface (37). While Gardnerella has been previously considered primarily responsible for sialidase activity in this environment, our work indicates that Prevotella species should also be included in future studies and considered in developing therapeutics targeting the vaginal microbiome. These findings highlight the need for further investigation into the biological roles of vaginal bacterial sialidases and their contributions to negative health outcomes.
Materials and Methods
Plasmid Construction.
Full-length sialidase genes were amplified (Q5 polymerase, New England Biolabs, M0492S) from purified genomic DNA (Qiagen, 12224-50) from vaginal bacteria (SI Appendix, Table S2) using primer pairs (SI Appendix, Table S1). The resulting gene products were assembled into pET28a expression vector (Novagen, 69864) using Gibson assembly (New England Biolabs, E2611S) and transformed into DH5α E. coli chemically competent cells. The identities of the constructs were confirmed by DNA sequencing (Genewiz). The confirmed plasmids were transformed into E. coli BL21 (DE3) for expression. All constructs were grown in LB (Research Products International, RPI, L24060-2000) containing 50 µg/mL kanamycin sulfate (VWR, 408-EU-25G).
Sialidases Used for Expression.
The protein accession numbers in the NCBI database for each enzyme characterized are as follows: G. vaginalis JCP8066 NanH3 (EPI58250.1), G. vaginalis ATCC14018 NanH1 (WP_013399386.1), P. bivia DNF00188 NanH (KGF23106.1), P. denticola DNF00960 (WP_036854057.1), and P. timonensis CRIS 5C-B1 NanH1 (WP_008123113.1) NanH2 (WP_008122213.1).
Heterologous Expression and Purification of Heterologously Expressed Enzymes.
Chemically competent E. coli BL21(DE3) cells were transformed with pET28 plasmids encoding Sialidases as N-terminal His6-tagged fusion proteins. The transformed cells were plated onto LBKAN agar plates, incubated at 37 °C overnight, and a single colony was used to grow a starter 3 mL culture and used to create a 20% glycerol stock. A 2.5 mL starter culture grown to saturation overnight was used to inoculate 1 L of LB (Research Products International, RPI) containing 50 µg/mL kanamycin. The 1 L culture was grown at 37 °C with shaking (180 rpm). When the culture reached an OD600 between 0.4 and 0.8, protein expression was induced by adding Isopropyl β-D-thiogalactoside (IPTG) (TEKNOVA, I3325) to a final concentration of 250 µM. The cultures were incubated at 16 °C with shaking (180 rpm) for 18 h. Cell cultures were then harvested by centrifugation at 6,000×g for 10 min at 4 °C and stored at −80 °C. Thawed cell pellets were resuspended in Buffer A containing 20 mM Tris, 500 mM NaCl, 10 mM MgSO4, 1 mM CaCl2, and 5 mM imidazole, and pH balanced at pH 7.5. The resuspended cells were supplemented with 0.1 mg/mL DNAse (Sigma, DN25-1G), 0.5 mg/mL Lysozyme (Sigma, L6876-10G), and Pierce Protease Inhibitor Tablets (Thermo Scientific, A32965). Cells were lysed using a cell disrupter (Emulsiflex-C3, Avestin) by passing three times at 15,000 psi, and cell lysates were clarified by centrifugation at 9,000 rpm for 45 min at 4 °C. The clarified lysate was transferred to a 15 mL column containing 3 mL Ni-NTA Agarose affinity resin equilibrated with buffer A at 4 °C (Invitrogen). The column was washed using a gradient of Buffer A containing 20 mM, 50 mM, 75 mM, and 100 mM imidazole. Protein was eluted with buffer A containing 250 mM imidazole. Fractions were analyzed by SDS-PAGE (Biorad, 4561086) and stained with InstantBlue Coomassie protein stain (Abcam, ab119211). The protein-containing fractions were pooled and concentrated in an Amicon spin concentrator of 10 to 30 kDa cutoff (Millipore, UCF901024 and UCF903024) and buffer exchanged against Buffer B (20 mM Tris, 100 mM NaCl, 10 mM MgSO4, 1 mM CaCl2, 10 % glycerol, pH 7.5). Protein aliquots of 20 µL were frozen in liquid nitrogen and stored at –80 °C. Protein concentrations were estimated with a NanoDrop 2000 UV–Vis Spectrophotometer (Thermo Scientific) using the theoretical molar absorption coefficient calculated using https://web.expasy.org/protparam/.
Sialidase Activity Screen in Vaginal Isolates.
Strains were grown anaerobically inside an anaerobic chamber with an atmosphere of 2.5 % H2, 5 % CO2, 92.5 % N2 (Coy Lab Products) in 96-well plates containing 200 µL of PYGT media (1 % glucose) supplemented with 10 % horse serum broth for 48 h. Cultures were then normalized to OD = 1 and 20 µL of culture was added to a black 96-well plate containing 350 µM 4-MU-Neu5Ac (Biosynth) dissolved in 80 µL of sodium acetate buffer pH 5.5. Fluorescence signal was monitored at 360/440 nm for 105 min in a plate reader (Biotek Synergy HTX) at 37 °C.
Activity Assays of Purified Sialidases.
Sialidase activity was measured using a fluorescence-based assay in a total volume of 100 µL, prepared in a black, 96-well polystyrene plate (Corning). Each well contained 2.5 nM purified enzyme in sodium acetate buffer (100 µM, pH 5.5) and 4-MU-Neu5Ac (200 µM) was added to start the sialidase reaction. Fluorescence 330/440 nm was measured while incubating at 37 °C with shaking in a plate reader (Biotek).
Kinetic Characterization.
Sialidase activity was measured using 2.5 nM purified enzyme in sodium acetate buffer (100 µM, pH 5.5) in a total volume of 100 µL. 4-MU-Neu5Ac was diluted to create a 12-step, 1:2 dilution series from 800 to 3.1 µM. Fluorescence 360/440 nm was measured while incubating at 37 °C with shaking in a plate reader (Biotek). Slopes were calculated over the first 5 min, and GraphPad was used to calculate Michaelis–Menten kinetic parameters, Vmax and Km.
pH Profiles of Sialidases.
The optimal pH for enzyme activity was determined by incubating 20 to 100 nM sialidases with 200 µM 4-MU-Neu5Ac in Mcllvaine buffer (0.1 M citric acid/0.2 M phosphate buffer) at a pH range of 3 to 8 for 30 min in at 37 °C. Activity was assayed by monitoring fluorescence 360/440 nm in a plate reader (Biotek). The assay was prepared in a 384-well, black, flat-bottom polystyrene plate (Corning). Fluorescence values were normalized to standard curves of 4-methylumbelliferone (Sigma) (concentration 200 to 1.5 µM) dissolved in DMSO and prepared in the same citrate/phosphate buffers from pH 3 to 8. Relative sialidase activity was determined by measuring the total concentration of 4-methylumbelliferone released at 29 min.
Sialidase Substrate Specificity Endpoint Assay.
To determine the substrate specificity of sialidases, 40 nM enzyme was incubated with the following substrates: 4-MU-Neu5Ac (250 µM), BSM (1 mg/mL), human serum IgA (0.5 mg/mL), human serum IgG (4 mg/mL), 3′sialyllactose (200 µM), 6′siallylactose (200 µM), MUC5B (0.5 mg/mL) in 20 mM sodium acetate buffer pH 5.5 in a total volume of 50 µL. All samples included N-acetyl-D-neuraminic acid-1,2,3-13C3 (Sigma, 649694) as an internal standard. The assays were incubated for 2 h at 37 °C in a thermocycler (Biorad). Samples were then filtered through 3 kDa filter plates and derivatized with 4,5-dimethoxy-1,2-phenylenediamine hydrochloride (DMB), (Sigma, 36271). To derivatize samples, 20 µL of filtered sample was mixed with 80 µL of derivatization reagent (6.5 mM DMB, 52 mM sodium dithionite, 0.75 M 2-mercaptoethanol, 1.33 M acetic acid). Samples were incubated at 50 °C for 2 h.
Anaerobic Culture Conditions.
All plastic consumables used for culturing were kept in the anaerobic chamber for at least 24 h prior to the experiment. Bacterial isolates were obtained from Biodefense and Emerging Infections Research Resources Repository (BEI Resources) SI Appendix, Table S2). Gardnerella and Prevotella strains were cultured in PYGT media as previously described (46) (20 g peptone, 10 g glucose, 10 g yeast extract, 0.4 g sodium bicarbonate, 40 mg dipotassium phosphate, 40 mg monopotassium phosphate, 5 mg hemin, 5 mg vitamin K, 0.25 g L-cysteine hydrochloride, 8 mg magnesium sulfate, 0.250 mL TWEEN-80, 50 mL heat-inactivated horse serum (Sigma), in 1 L of filter-sterilized water (0.2 µm), containing 10 % inactivated horse serum. Medium was transferred to an anaerobic chamber with an atmosphere containing 2.5 % H2, 5 % CO2 and 92.5 % N2 (Coy Labs). Starter cultures of Gardnerella and Prevotella were inoculated in 96-well plates containing 200 µL of PYGT and incubated at 37 °C overnight.
Sialic Acid Detection by DMB Labeling and LC–MS Analysis.
Derivatized samples were prepared for analysis by diluting 1:100 in 90:10 acetonitrile (ACN): water. See derivatization procedure in SI Appendix, Supplemental Methods. Samples were analyzed by ultra-high-performance model Xevo TQ-S (Waters, UPLC-MS/MS), see SI Appendix, Supplemental Methods and Materials (SI Appendix, Table S4).
MUC5B Purification.
Submandibular saliva was collected in bulk from human volunteers using a custom vacuum pump, as described previously (38, 47). We collected the saliva samples after explaining the nature and possible consequences of the studies, obtaining written informed consent, and receiving approval from the institutional review board and Massachusetts Institute of Technology (MIT)’s Committee on the Use of Humans as Experimental Subjects under protocol #1312006096. Immediately after collection, salts, antibacterial agents, and protease inhibitors were added to the saliva to reach a final concentration of 0.16 M NaCl, 5 mM benzamidine HCl, 1 mM dibromoacetophenone, 1 mM phenylmethylsulfonyl fluoride, and 5 mM EDTA. The mucins in the saliva were solubilized overnight by stirring gently at 4 °C. Solubilized saliva was then flash-cooled in liquid nitrogen in 10 to 40 mL volumes and stored at –80 °C. Before chromatography, 200 mL of saliva from separate donors was thawed at 4 °C, and insoluble material was removed by centrifugation at 10,000×g for 10 min at 4 °C. MUC5B was purified using a Bio-Rad NGC fast protein liquid chromatography (FPLC) system equipped with an XK 50 column packed with 2 L of Sepharose CL-2B resin (GE Healthcare Bio-Sciences). Mucin-containing fractions were identified using a periodic acid–Schiff's reagent assay and analysis of UV absorbance at 280 nm from FPLC. Fractions were then combined, dialyzed, and concentrated using an ultrafiltration device and were then lyophilized for storage at −80 °C. Protocols involving the use of human subjects were approved by Massachusetts Institute of Technology’s Committee on the Use of Humans as Experimental Subjects.
Inhibition of Purified Sialidases.
Sialidase inhibition assays were performed using 5 nM purified enzyme in sodium acetate buffer (100 µM, pH 5.5) and with varying concentrations of Neu5ac2en (Sigma, D9050) in a total volume of 50 µL. Each well contained 1 µL of enzyme was premixed with 39 µL of buffer and 5 µL of inhibitor in a black 384-well flat-bottom polystyrene plate (Corning) and 5 µL of 4-MU-Neu5Ac (100 µM final concentration) was added to start the assay. The plate was immediately transferred into the plate reader to incubate at 37 °C with shaking to measure fluorescence 360/440 nm. For improved accuracy, the enzyme, inhibitor, and 4-MU-Neu5Ac were dispensed into the plate using a Formulatrix MANTIS. Slopes to determine sialidase activity were calculated over the first 5 min, and the IC50 were determined by nonlinear fit [Inhibitor] vs. response on GraphPad Prism.
Bacterial Genomic Database and HMM-Based Sialidase Searches of Isolate Genomes.
A bacterial isolate genomic database was constructed using 1,189 published genomes from the Vaginal Microbiome Research Consortia, spanning cohorts from the United States and South Africa (Full list and metadata provided in Supplementary data file). Bacterial genomes were organized by phylogeny (SI Appendix, Figs. S10, S11, S13, and S15) using a concatenated ribosomal protein tree. We used HMMER (v3.3.2) to find ribosomal proteins, aligned the sequences with MAFFT (v7.508) and used RAxML (v.8.2.10) to create the phylogenetic trees. In order to search our diverse collection of vaginal bacterial genomes for putative sialidases, we used HMMER (v3.3.2) to construct a hidden Markov model using a database made of a multiple sequence alignment of nine sialidase genes (See supplementary fasta file A) constructed with MAFFT (v7.508). We required all hits to be greater than 250 amino acids in length (SI Appendix, Supplementary Fasta File B) and validated hits manually by searching for predicted sialidase domains using InterProScan.
MG and MT Searches and Quantification.
Diamond blastX was used to quantify the abundance of sialidase encoding genes and transcripts in MG and MT published by the Vaginal Microbiome Research Consortium (VMRC). First, we compiled all the candidate sialidase genes identified by HMMER and created representative sequences using CD-hit with >85 % amino acid ID. After representative sequences were generated, they were used in Diamond blastX with a e-value cutoff of <e-20 and a percent amino acid sequence identity >50 % to determine the abundance of these sialidases in MG and MT databases generated by the VMRC under the Bioproject PRJNA797778. By setting a stringent identity and e value cutoff, we are quantifying high confidence hits to specific sialidase genes queried. The scripts for processing the datasets were described previously (21). We analyzed 176 paired MG and MT from 40 patients. The output from diamond blastx is RPKM. Sample metadata was used to bin the results by community state type (CSTI n = 39, CSTII n = 16, CSTIII n = 31, CSTIV n = 80, CSTV n = 10). The total expression per sample was calculated by summing all the RPKM values for all the candidate sialidases for each sample. Prevalence is defined by detecting any sialidase read in a sample. Percent contribution of a sialidase is determined by the relative abundance of one sialidase divided by the sum of all sialidase abundances within each sample. Plots were generated using Python 3 and PRISM.
Supplementary Material
Appendix 01 (PDF)
Dataset S01 (XLSX)
Acknowledgments
We thank Karin Strijbis and Celia Sequi Perez for critical reading and editing of the manuscript. We thank Wei Li for assistance with cloning the Gardnerella sialidases. We acknowledge Beverly Fu, Min Woo Bae, and Grace Kenney for providing advice regarding bioinformatic analyses. We thank all the members of the Vaginal Microbiome Research Consortium for helpful discussions. We acknowledge funding from the Bill and Melinda Gates Foundation (Awards No. 270790 and INV-037720). E.P.B. is a HHMI Investigator. P.P. was supported by the NSF Graduate Research Fellowship (NSF-GRFP). F.A.H. was supported by the Schmidt Science Fellowship. D.S.K. was supported by the Bill and Melinda Gates Foundation (Awards INV-048977 and OPP1189208). This article is subject to HHMI’s Open Access to Publications policy. HHMI lab heads have previously granted a nonexclusive CC BY 4.0 license to the public and a sublicensable license to HHMI in their research articles. Pursuant to those licenses, the author-accepted manuscript of this article can be made freely available under a CC BY 4.0 license immediately upon publication.
Author contributions
P.P. and E.P.B. designed research; P.P. and C.M.X. performed research; C.A.W., C.M.W., B.M.W., L.R., M.T.F., J.R., K.R., and D.S.K. contributed new reagents/analytic tools; P.P. and F.A.H. analyzed data; and P.P., F.A.H., and E.P.B. wrote the paper.
Competing interests
J.R. is a cofounder of LUCA Biologics, a biotechnology company focusing on translating microbiome research into live biotherapeutic drugs for women’s health. D.S.K. serves as equity holder of Day Zero Diagnostics.
Footnotes
This article is a PNAS Direct Submission.
Data, Materials, and Software Availability
The bacterial isolate genomes are publicly available under the BioProject accession codes: PRJNA799634 (48), PRJNA799744 (49), PRJNA799737 (50), PRJNA799746 (51), and PRJNA797778 (52). Experimental data have been deposited in Synapse.org (https://doi.org/10.7303/syn53254095) (53). Previously published data were used for this work (21).
Supporting Information
References
- 1.Ravel J., et al. , Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. U.S.A. 108, 4680–4687 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Fettweis J. M., et al. , The vaginal microbiome and preterm birth. Nat. Med. 25, 1012–1021 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Gosmann C., et al. , Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity 46, 29–37 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cauci S., McGregor J., Thorsen P., Grove J., Guaschino S., Combination of vaginal pH with vaginal sialidase and prolidase activities for prediction of low birth weight and preterm birth. Am. J. Obstet. Gynecol. 192, 489–496 (2005). [DOI] [PubMed] [Google Scholar]
- 5.Cauci S., Culhane J. F., High sialidase levels increase preterm birth risk among women who are bacterial vaginosis-positive in early gestation. Am. J. Obstet. Gynecol. 204, e1–142.e9 (2011). [DOI] [PubMed] [Google Scholar]
- 6.Briselden A. M., Moncla B. J., Stevens C. E., Hillier S. L., Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora. J. Clin. Microbiol. 30, 663–666 (1992). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Smayevsky J., Canigia L. F., Lanza A., Bianchini H., Vaginal microflora associated with bacterial vaginosis in nonpregnant women: Reliability of sialidase detection. Infect. Dis. Obstet. Gynecol. 9, 17 (2001). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Myziuk L., Romanowski B., Johnson S. C., BVBlue test for diagnosis of bacterial vaginosis. J. Clin. Microbiol. 41, 1925–1928 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Andersch-Björkman Y., Thomsson K. A., Holmén Larsson J. M., Ekerhovd E., Hansson G. C., Large scale identification of proteins, mucins, and their O-glycosylation in the endocervical mucus during the menstrual cycle. Mol. Cell. Proteomics 6, 708–716 (2007). [DOI] [PubMed] [Google Scholar]
- 10.Safaeian M., et al. , Factors associated with IgA and IgG fluctuations at the cervix during the menstrual cycle. J. Infect. Dis. 199, 455 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Vattepu R., Sneed S. L., Anthony R. M., Sialylation as an important regulator of antibody function. Front. Immunol. 13, 1571 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Critchfield A. S., et al. , Cervical mucus properties stratify risk for preterm birth. PLoS ONE 8, e69528 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Robinson L. S., Schwebke J., Lewis W. G., Lewis A. L., Identification and characterization of NanH2 and NanH3, enzymes responsible for sialidase activity in the vaginal bacterium Gardnerella vaginalis. J. Biol. Chem. 294, 5230–5245 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Hardy L., et al. , The presence of the putative Gardnerella vaginalis sialidase A gene in vaginal specimens is associated with bacterial vaginosis biofilm. PLoS ONE 12, e0172522 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Kurukulasuriya S. P., Patterson M. H., Hill J. E., Slipped-strand mispairing in the gene encoding sialidase NanH3 in Gardnerella spp. Infect. Immun. 89, e00583-20 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Lopes Dos Santos Santiago G., et al. , Gardnerella vaginalis comprises three distinct genotypes of which only two produce sialidase. Am. J. Obstet. Gynecol. 204, e1–450.e7 (2011). [DOI] [PubMed] [Google Scholar]
- 17.Lewis W. G., Robinson L. S., Gilbert N. M., Perry J. C., Lewis A. L., Degradation, foraging, and depletion of mucus sialoglycans by the vagina-adapted Actinobacterium Gardnerella vaginalis. J. Biol. Chem. 288, 12067–12079 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Kurukulasuriya S., Characterization of Sialidase Enzymes of spp. (University of Saskatchewan, 2020). [Google Scholar]
- 19.Moncla B. J., Braham P., Hillier S. L., Sialidase (neuraminidase) activity among gram-negative anaerobic and capnophilic bacteria. J. Clin. Microbiol. 28, 422–425 (1990). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Ilhan Z. E., Łaniewski P., Tonachio A., Herbst-Kralovetz M. M., Members of Prevotella genus distinctively modulate innate immune and barrier functions in a human three-dimensional endometrial epithelial cell model. J. Infect. Dis. 222, 2082–2092 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.France M. T., et al. , Insight into the ecology of vaginal bacteria through integrative analyses of metagenomic and metatranscriptomic data. Genome Biol. 23, 1–26 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Mitchell C. M., et al. , Colonization of the upper genital tract by vaginal bacterial species in nonpregnant women. Am. J. Obstet. Gynecol. 212, e1–611.e9 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Mikamo H., et al. , Bacterial isolates from patients with preterm labor with and without preterm rupture of the fetal membranes. Infect. Dis. Obstet. Gynecol. 7, 180–194 (1999). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Gilbert N. M., et al. , Gardnerella vaginalis and Prevotella bivia trigger distinct and overlapping phenotypes in a mouse model of bacterial vaginosis. J. Infect. Dis. 220, 1099–1108 (2019), 10.1093/infdis/jiy704. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Park K. H., et al. , Structural and biochemical characterization of the broad substrate specificity of Bacteroides thetaiotaomicron commensal sialidase. Biochim. Biophys. Acta Proteins Proteom. 1834, 1510–1519 (2013). [DOI] [PubMed] [Google Scholar]
- 26.Jumper J., et al. , Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Li W., et al. , 9-Azido-9-deoxy-2,3-difluorosialic acid as a subnanomolar inhibitor against bacterial sialidases. J. Org. Chem. 84, 6697–6708 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Lewis W. G., et al. , Hydrolysis of secreted sialoglycoprotein immunoglobulin A (IgA) in ex vivo and biochemical models of bacterial vaginosis. J. Biol. Chem. 287, 2079–2089 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Wang Y. Y., et al. , IgG in cervicovaginal mucus traps HSV and prevents vaginal Herpes infections. Mucosal Immunol. 7, 1036–1044 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Usala S. J., Usala F. O., Haciski R., Holt J. A., Schumacher G. F., IgG and IgA content of vaginal fluid during the menstrual cycle. J. Reprod. Med. 34, 292–294 (1989). [PubMed] [Google Scholar]
- 31.Iwamori M., Ohta Y., Uchida Y., Tsukada Y., Arthrobacter ureafaciens sialidase isoenzymes, L, m1 and m2, cleave fucosyl GM1. Glycoconj. J. 14, 67–73 (1997). [DOI] [PubMed] [Google Scholar]
- 32.Zaramela L. S., et al. , Gut bacteria responding to dietary change encode sialidases that exhibit preference for red meat-associated carbohydrates. Nat. Microbiol. 4, 2082–2089 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Lopes Dos Santos Santiago G., et al. , Gardnerella vaginalis comprises three distinct genotypes of which only two produce sialidase. Am. J. Obstet. Gynecol. 204, e1–450.e7 (2011). [DOI] [PubMed] [Google Scholar]
- 34.Yamaguchi M., et al. , Evolutionary inactivation of a sialidase in group B Streptococcus. Sci. Rep. 6, 28852 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Ng S., et al. , Large-scale characterisation of the pregnancy vaginal microbiome and sialidase activity in a low-risk Chinese population. npj Biofilms Microbiomes 7, 1–11 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Lewis A. L., Lewis W. G., Host sialoglycans and bacterial sialidases: A mucosal perspective. Cell Microbiol. 14, 1174–1182 (2012). [DOI] [PubMed] [Google Scholar]
- 37.Segui-Perez C., et al. , Prevotella timonensis degrades the vaginal epithelial glycocalyx through high fucosidase and sialidase activities. bioRxiv [Preprint] (2024). 10.1101/2024.01.09.574844 (Accessed 9 January 2024). [DOI] [PMC free article] [PubMed]
- 38.Werlang C. A., et al. , Mucin O-glycans suppress quorum-sensing pathways and genetic transformation in Streptococcus mutans. Nat. Microbiol. 6, 574–583 (2021), 10.1038/s41564-021-00876-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Agarwal K., et al. , Resident microbes shape the vaginal epithelial glycan landscape. Sci. Transl. Med. 15, eabp9599 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Govinden G., et al. , Inhibition of sialidase activity and cellular invasion by the bacterial vaginosis pathogen Gardnerella vaginalis. Arch. Microbiol. 200, 1129–1133 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.McCombs J. E., Diaz J. P., Luebke K. J., Kohler J. J., Glycan specificity of neuraminidases determined in microarray format. Carbohydr. Res. 428, 31–40 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Castro J., Rosca A. S., Muzny C. A., Cerca N., Atopobium vaginae and Prevotella bivia are able to incorporate and influence gene expression in a pre-formed Gardnerella vaginalis biofilm. Pathogens 10, 247 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Ferreira C. S. T., Marconi C., Parada C. M. G. L., Ravel J., da Silva M. G., Sialidase activity in the cervicovaginal fluid is associated with changes in bacterial components of Lactobacillus-deprived microbiota. Front. Cell. Infect. Microbiol. 11, 1321 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Wiggins R., et al. , Use of 5-bromo-4-chloro-3-indolyl-α-d-n-acetylneuraminic acid in a novel spot test to identify sialidase activity in vaginal swabs from women with bacterial vaginosis. J. Clin. Microbiol. 38, 3096–3097 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Pollak S., et al. , Public good exploitation in natural bacterioplankton communities. Sci. Adv. 7, 4717–4745 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Jenkins D. J., et al. , Bacterial amylases enable glycogen degradation by the vaginal microbiome. Nat. Microbiol. 8, 1641–1652 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Frenkel E. S., Ribbeck K., Salivary mucins protect surfaces from colonization by cariogenic bacteria. Appl. Environ. Microbiol. 81, 332–338 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Kwon D., FRESH (Females Rising through Education, Support, and Health). National Center for Biotechnology Information BioProject database. https://www.ncbi.nlm.nih.gov/bioproject/PRJNA799634. Deposited 3 March 2022.
- 49.Mitchell C., V2 - premenopausal women presenting to the Vulvovaginal Disorders. National Center for Biotechnology Information BioProject database. https://www.ncbi.nlm.nih.gov/bioproject/PRJNA799744. Deposited 3 March 2022.
- 50.Marrazzo J. M., Bacterial isolations derived from Vaginal Health Project samples. National Center for Biotechnology Information BioProject database. https://www.ncbi.nlm.nih.gov/bioproject/PRJNA799737. Deposited 3 March 2022.
- 51.Kwon D., Kwon Ragon Resequence Reference Isolates. National Center for Biotechnology Information BioProject database. https://www.ncbi.nlm.nih.gov/bioproject/PRJNA799746. Deposited 3 March 2022.
- 52.France M. T., Ravel J., Vaginal Microbiome Research Consortium.National Center for Biotechnology Information BioProject database. https://www.ncbi.nlm.nih.gov/bioproject/PRJNA797778. Deposited 16 January 2022.
- 53.Pelayo P., et al. , Prevotella are major contributors of sialidases in the human vaginal microbiome. Synapse data repository. 10.7303/syn53254095. Deposited 10 January 2024. [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Appendix 01 (PDF)
Dataset S01 (XLSX)
Data Availability Statement
The bacterial isolate genomes are publicly available under the BioProject accession codes: PRJNA799634 (48), PRJNA799744 (49), PRJNA799737 (50), PRJNA799746 (51), and PRJNA797778 (52). Experimental data have been deposited in Synapse.org (https://doi.org/10.7303/syn53254095) (53). Previously published data were used for this work (21).